CA-FORESCOUT
24.1.2024 07:02:27 CET | Business Wire | Press release
In the last year, the world’s critical infrastructure – the medical, power, communications, waste, manufacturing, and transportation equipment that connects people and machines – has been under near-constant attack. Forescout Research – Vedere Labs recorded more than 420 million attacks between January and December 2023. That is 13 attacks per second, a 30% increase from 2022.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240123671589/en/
2023 Global Threat Roundup Highlights from Forescout Research (Graphic: Business Wire)
Forescout, a global cybersecurity leader, unveiled the global findings of recorded attacks in its Adversary Engagement Environment (AEE) in the new report, “2023 Global Threat Roundup.” The AEE is maintained by Vedere Labs, a leading global team dedicated to uncovering vulnerabilities in and threats to critical infrastructure.
Despite the formidable challenges posed by the ongoing surge in cyber-activity, there is an optimistic path forward. Elisa Costante, VP of Research at Forescout Research – Vedere Labs, highlights the potential for positive change, stating, "While it's true that current efforts have fallen short in fully harnessing crucial technology to fortify critical assets and assess risks, there is an opportunity for improvement."
Read the blog: 2023 Global Threat Roundup: Trends in Cyberattacks, Exploits and Malware
Here are the top five insights from Forescout Research:
-
Not Yet Dormant: Log4j Dampens Software Library Exploits
Exploits against software libraries are witnessing a decline due to the waning popularity of Log4j exploits. This lull has given rise to a surge in exploits targeting network infrastructure and Internet of Things (IoT) devices.
Among the IoT landscape, the spotlight falls on IP cameras, building automation systems, and network-attached storage, emerging as the most sought-after targets for malicious actors.
Only 35% of exploited vulnerabilities made an appearance in the Cybersecurity and Infrastructure Security Agency's (CISA) Known Exploited Vulnerabilities (KEV) list. This divergence emphasizes the need for a proactive and comprehensive approach to cybersecurity, transcending reliance on known vulnerability databases.
-
OT Protocols Bear the Brunt
Operational Technology (OT) finds itself under relentless assault, with five key protocols bearing the brunt of persistent attacks. The primary targets include protocols used in industrial automation and power sectors, such as Modbus, subject to a staggering one-third of all attacks, closely followed by Ethernet/IP, Step7, and DNP3, each accounting for approximately 18% of the onslaught. IEC10X rounds out this list with 10% of attacks, leaving the remaining 2% distributed among various protocols, with BACnet emerging as the majority.
Building automation protocols, such as BACnet, experience less frequent scans. However, the relative scarcity of scans belies an alarming trend—targeted exploits against vulnerabilities in building automation devices are more prevalent.
-
Post-Exploitation Tactics Shift
Persistence tactics mark a 50% surge from 3% in 2022, along with discovery (roughly 25%) and execution (the other roughly 25%). While most observed commands used by threat actors remain targeted at generic Linux systems, a notable trend involves specific commands executed for network operating systems found on widely used routers.
-
Malware Families Remain Strong
Malware families persist as formidable threats. The Agent Tesla Remote Access Trojan (RAT) commands a significant 16% share of observed malicious activity. Following closely are variants of the Mirai botnet, comprising 15%, and the Redline info stealer, holding its ground at 10%.
Among command-and-control servers, Cobalt Strike emerges as the undisputed leader, commanding a substantial 46% share, trailed by Metasploit at 16%, and the emerging Sliver C2 at 13%. Most of these servers are in the United States, constituting 40% of the global landscape, with China and Russia following at 10% and 8%, respectively.
-
Threats Unleashed Across 163 Countries
Threat actors have cast a digital net far and wide, impacting 163 countries. The United States stands as the primary target, bearing the brunt with 168 malicious actors setting their sights on the nation. Other countries include the United Kingdom (88), Germany (77), India (72), and Japan (66).
The usual suspects boast high concentrations of threat actors: China (155), Russia (88), and Iran (45), collectively representing nearly half of all identified threat groups. The crosshairs of these malicious entities are predominantly fixed on three key sectors: Government, Financial Services, and Media and Entertainment. As the primary pillars of societal infrastructure, these industries are at the forefront of cyber warfare, emphasizing the need for heightened security measures and collaborative efforts.
Costante continues, “The key lies in achieving comprehensive visibility, ensuring real-time contextual awareness of every device, whether managed or unmanaged. By doing so, large enterprises can transition from a reactive defense posture to a more proactive approach, steering clear of the futile game of security whack-a-mole. This shift towards enhanced visibility and proactive defense strategies signals a brighter outlook for critical infrastructure.”
For more information, download the full report, “2023 Global Threat Roundup,” now at https://www.forescout.com/resources/research-report_2023-threat-roundup.
How Forescout Research Works
Forescout Research employs its Adversary Engagement Environment (AEE) to conduct analysis, leveraging a blend of real and simulated connected devices. This dynamic environment functions as a robust tool, enabling the pinpointing of incidents and the identification of intricate threat actor patterns at a granular level. The overarching objective is to elevate responses to complex critical infrastructure attacks by leveraging the detailed insights and understanding derived from this specialized deception environment. The AEE is maintained by Vedere Labs, a leading global team dedicated to uncovering vulnerabilities in and threats to critical infrastructure. Forescout products directly leverage this research, which is also shared openly with vendors, agencies, and other researchers.
About Forescout
Forescout Technologies, Inc., a global cybersecurity leader, continuously identifies, protects and helps ensure the compliance of all managed and unmanaged connected cyber assets – IT, IoT, IoMT and OT. For more than 20 years, Fortune 100 organizations and government agencies have trusted Forescout to provide vendor-agnostic, automated cybersecurity at scale. The Forescout® Platform delivers comprehensive capabilities for network security, risk and exposure management, and extended detection and response. With seamless context sharing and workflow orchestration via ecosystem partners, it enables customers to more effectively manage cyber risk and mitigate threats.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240123671589/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 08:00:00 CEST | Press release
Employee-led recognition places Boomi among the UK's top medium-sized employers, with a flight risk of just 3% against a technology sector average of 42% Boomi achieves an average employee happiness score of 86%, rated Excellent across all six dimensions of WorkL's workplace framework Flight risk of just 3%, compared to a technology sector average of 42%, reflecting exceptional levels of employee loyalty Rated Excellent for Diversity and Inclusion and Confidence in Management Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.b
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
